Otilonium bromide in irritable bowel syndrome: A dose-ranging randomized double-blind placebo-controlled trial

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 34

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Gastroenterol. Sep 14, 2014; 20(34): 12283-12291
Published online Sep 14, 2014. doi: 10.3748/wjg.v20.i34.12283

Full Size Figure Download Figure

Figure 1 Patient disposition. OB: Otilonium bromide.

Citation: Chmielewska-Wilkoń D, Reggiardo G, Egan CG. Otilonium bromide in irritable bowel syndrome: A dose-ranging randomized double-blind placebo-controlled trial. World J Gastroenterol 2014; 20(34): 12283-12291
URL: https://www.wjgnet.com/1007-9327/full/v20/i34/12283.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i34.12283

Chmielewska-Wilkoń D, Reggiardo G, Egan CG. Otilonium bromide in irritable bowel syndrome: A dose-ranging randomized double-blind placebo-controlled trial. World J Gastroenterol 2014; 20(34): 12283-12291 [PMID: 25232263 DOI: 10.3748/wjg.v20.i34.12283]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.